Sonali Chaudhury
Research Subjects
Sonali Chaudhury has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
Nobuko Hijiya
Division of Hematology/Oncology/Stem Cell Transplant, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois
3 shared publicationsGregory Hale
Johns Hopkins All Children's Hospital, St. Petersburg, Florida
2 shared publications- Jeffrey J. Bednarski
Washington University in St. Louis, Saint Louis, Missouri, United States
2 shared publications - Jeffrey R. Andolina
Pediatric Hematology/Oncology University of Rochester Medical Center Rochester New York USA
2 shared publications - Jennifer Schneiderman
Division of Pediatric Hematology/Oncology/Neuro‐Oncology/Stem Cell Transplant, Ann & Robert H. Lurie Children’s Hospital of Chicago Northwestern University Feinberg School of Medicine Chicago Illinois USA
2 shared publications - Michael A. Pulsipher
Division of Pediatric Hematology and Oncology, Intermountain Primary Children's Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT
2 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (8) , e0069926
Plasma metagenomic sequencing testing for diagnosis of invasive fungal infection in children and young adults
Invasive fungal infection (IFI) is challenging to diagnose, often involving invasive sampling. Plasma cell-free metagenomic next-generation sequencing (mNGS) has shown promise in diagnosing infections, but data are limited on specific clinical scenarios in which this test is most helpful. We conducted a retrospective single-center study of children and young adults with high-risk conditions evaluated for IFI between December 2016 and November 2024. Clinical concern for IFI was indicated by (i) evaluation with both serum β-D-glucan and galactomannan testing, (ii) either or both of CT scans of sinuses and chest, and (iii) antifungal treatment either started or broadened. Episodes in which mNGS testing was sent within 30 days of initiation or broadening of antifungal coverage were evaluated to determine the diagnostic performance of mNGS testing, using EORTC-MSG criteria for proven or probable IFI as the comparator. We identified 227 episodes in 180 high-risk patients consistent with clinical concern for IFI. Of these, 45 episodes met EORTC-MSG criteria for proven/probable IFI. Plasma mNGS testing was sent in 36 episodes and identified the causative organism in 28. Positive and negative percent agreement for diagnosis of proven/probable IFI in this population was 77.8% and 90.4%, respectively. Among proven/probable cases with mNGS testing, Candida and Aspergillus were the most commonly identified fungi. Plasma mNGS testing in pediatric and young adult patients at risk for IFI compares favorably with diagnostic criteria used for IFI diagnosis and may be added to the diagnostic evaluation of patients at high-risk of IFI. IMPORTANCE: Performance of plasma mNGS testing for diagnosis of invasive fungal infection in high-risk pediatric and young adult patients was comparable to the combination of fungal culture and targeted PCR from invasively acquired samples, suggesting that it might allow earlier diagnosis for some patients.
- 4 August 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (8) , e0069926
Open AccessPlasma metagenomic sequencing testing for diagnosis of invasive fungal infection in children and young adults
Invasive fungal infection (IFI) is challenging to diagnose, often involving invasive sampling. Plasma cell-free metagenomic next-generation sequencing (mNGS) has shown promise in diagnosing infections, but data are limited on specific clinical scenarios in which this test is most helpful. We conducted a retrospective single-center study of children and young adults with high-risk conditions evaluated for IFI between December 2016 and November 2024. Clinical concern for IFI was indicated by (i) evaluation with both serum β-D-glucan and galactomannan testing, (ii) either or both of CT scans of sinuses and chest, and (iii) antifungal treatment either started or broadened. Episodes in which mNGS testing was sent within 30 days of initiation or broadening of antifungal coverage were evaluated to determine the diagnostic performance of mNGS testing, using EORTC-MSG criteria for proven or probable IFI as the comparator. We identified 227 episodes in 180 high-risk patients consistent with clinical concern for IFI. Of these, 45 episodes met EORTC-MSG criteria for proven/probable IFI. Plasma mNGS testing was sent in 36 episodes and identified the causative organism in 28. Positive and negative percent agreement for diagnosis of proven/probable IFI in this population was 77.8% and 90.4%, respectively. Among proven/probable cases with mNGS testing, Candida and Aspergillus were the most commonly identified fungi. Plasma mNGS testing in pediatric and young adult patients at risk for IFI compares favorably with diagnostic criteria used for IFI diagnosis and may be added to the diagnostic evaluation of patients at high-risk of IFI. IMPORTANCE: Performance of plasma mNGS testing for diagnosis of invasive fungal infection in high-risk pediatric and young adult patients was comparable to the combination of fungal culture and targeted PCR from invasively acquired samples, suggesting that it might allow earlier diagnosis for some patients.
- Open Access
- 7 July 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (5) , e20250231
Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report
Winestone et al. demonstrate that in 796 children with SCID transplanted with nonsibling donors between 1982 and 2020, survival was 18.8% lower among Black patients, 14.4% lower among Asian/Pacific Islander patients, and 6.9% lower among Hispanic patients compared with non-Hispanic White patients (P < 0.01). Newborn screening for SCID mitigates wide disparities between Black and non-Hispanic White patients.
- 7 July 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (5) , e20250231
Open AccessNewborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report
Winestone et al. demonstrate that in 796 children with SCID transplanted with nonsibling donors between 1982 and 2020, survival was 18.8% lower among Black patients, 14.4% lower among Asian/Pacific Islander patients, and 6.9% lower among Hispanic patients compared with non-Hispanic White patients (P < 0.01). Newborn screening for SCID mitigates wide disparities between Black and non-Hispanic White patients.
- Open Access
Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium
Improvements in survival have been made over the past two decades for childhood acute myeloid leukemia (AML), but the approximately 40% of patients who relapse continue to have poor outcomes. A combination of checkpoint-inhibitor nivolumab and azacitidine has demonstrated improvements in median survival in adults with AML. This phase I/II study with nivolumab and azacitidine in children with relapsed/refractory AML (NCT03825367) was conducted through the Therapeutic Advances in Childhood Leukemia & Lymphoma consortium. Thirteen patients, median age 13.7 years, were enrolled. Patients had refractory disease with multiple reinduction attempts. Twelve evaluable patients were treated at the recommended phase II dose (established at dose level 1, 3 mg/kg/dose). Four patients (33%) maintained stable disease. This combination was well tolerated, with no dose-limiting toxicities observed. Grade 3–4 adverse events (AEs) were primarily hematological. Febrile neutropenia was the most common AE ≥ grade 3. A trend to improved quality of life was noted. Increases in CD8+ T cells and reductions in CD4+/CD8+ T cells and demethylation were observed. The combination was well tolerated and had an acceptable safety profile in pediatric patients with relapsed/refractory AML. Future studies might explore this combination for the maintenance of remission in children with AML at high risk of relapse.
Open AccessNivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium
Improvements in survival have been made over the past two decades for childhood acute myeloid leukemia (AML), but the approximately 40% of patients who relapse continue to have poor outcomes. A combination of checkpoint-inhibitor nivolumab and azacitidine has demonstrated improvements in median survival in adults with AML. This phase I/II study with nivolumab and azacitidine in children with relapsed/refractory AML (NCT03825367) was conducted through the Therapeutic Advances in Childhood Leukemia & Lymphoma consortium. Thirteen patients, median age 13.7 years, were enrolled. Patients had refractory disease with multiple reinduction attempts. Twelve evaluable patients were treated at the recommended phase II dose (established at dose level 1, 3 mg/kg/dose). Four patients (33%) maintained stable disease. This combination was well tolerated, with no dose-limiting toxicities observed. Grade 3–4 adverse events (AEs) were primarily hematological. Febrile neutropenia was the most common AE ≥ grade 3. A trend to improved quality of life was noted. Increases in CD8+ T cells and reductions in CD4+/CD8+ T cells and demethylation were observed. The combination was well tolerated and had an acceptable safety profile in pediatric patients with relapsed/refractory AML. Future studies might explore this combination for the maintenance of remission in children with AML at high risk of relapse.
- Open Access
- 21 March 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (3) , 959
Co-Occurring X-Linked Agammaglobulinemia and X-Linked Chronic Granulomatous Disease: Two Isolated Pathogenic Variants in One Patient
We present a unique and unusual case of a male patient diagnosed with two coexisting and typically unassociated X-linked conditions: he was initially diagnosed with X-linked agammaglobulinemia (XLA) followed by a diagnosis of X-linked chronic granulomatous disease (XCGD) and an as of yet unpublished hypomorphic gp91phox variant in the CYBB gene. The latter was tested after the finding of granulomatous gingivitis. Hematopoietic stem cell transplant (HSCT) was performed due to severe colitis and nodular regenerative hyperplasia (NRH) of the liver. Following transplant, complete donor engraftment was observed with the restoration of a normal oxidative burst and full restoration of normal levels of circulating, mature CD19+ B cells. This case is singular in that it does not involve a contiguous gene syndrome in which deleted genes are in close proximity to either BTK and CYBB, which has been previously reported. To our knowledge, this is the first reported case of XLA and XCGD co-existing in a single patient and of having both inborn errors of immunity successfully treated by HSCT.
- 21 March 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (3) , 959
Open AccessCo-Occurring X-Linked Agammaglobulinemia and X-Linked Chronic Granulomatous Disease: Two Isolated Pathogenic Variants in One Patient
We present a unique and unusual case of a male patient diagnosed with two coexisting and typically unassociated X-linked conditions: he was initially diagnosed with X-linked agammaglobulinemia (XLA) followed by a diagnosis of X-linked chronic granulomatous disease (XCGD) and an as of yet unpublished hypomorphic gp91phox variant in the CYBB gene. The latter was tested after the finding of granulomatous gingivitis. Hematopoietic stem cell transplant (HSCT) was performed due to severe colitis and nodular regenerative hyperplasia (NRH) of the liver. Following transplant, complete donor engraftment was observed with the restoration of a normal oxidative burst and full restoration of normal levels of circulating, mature CD19+ B cells. This case is singular in that it does not involve a contiguous gene syndrome in which deleted genes are in close proximity to either BTK and CYBB, which has been previously reported. To our knowledge, this is the first reported case of XLA and XCGD co-existing in a single patient and of having both inborn errors of immunity successfully treated by HSCT.
- Open Access
- 25 January 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (2) , 570-583
A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy
Patients with sickle cell disease (SCD) and thalassemia experience several complications across their lifespan that lead to impairment in different health-related quality of life (HRQOL) domains. There is increasing interest in curative therapies for patients with SCD and thalassemia, including hematopoietic stem cell transplant (HSCT) and gene therapy; however, the effect of these therapies on various HRQOL domains remains unclear. Our objective was to systematically evaluate the most recent evidence for the effect of HSCT and gene therapy on HRQOL in patients with SCD and thalassemia. A systematic search of medical literature databases was conducted. A total of 16 studies (thalassemia, n = 9; SCD, n = 6; both, n = 1) involving 517 participants met inclusion criteria (thalassemia, n = 416; SCD, n = 101). HSCT was associated with a small to large positive effects in most HRQOL domains (Cohen’s d; mean = 0.47; median = 0.37; range, 0.27-2.05). In thalassemia, HSCT was frequently associated with large positive effects in physical and emotional HRQOL domains (median d = 0.79 and d = 0.57, respectively). In SCD, HSCT was associated with large positive effects in all HRQOL domains. Emerging data suggest improvement in HRQOL outcomes across different domains following gene therapy in thalassemia and SCD. The quality of evidence was moderate in 13 studies (81%). HSCT has a positive impact on several HRQOL domains in patients with SCD and thalassemia; however, more longitudinal studies are warranted to assess the sustainability of these effects. Reporting HRQOL outcomes from ongoing gene therapy or gene-editing trials in SCD and thalassemia is key to better understand the benefits of such therapies.
- 25 January 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (2) , 570-583
Open AccessA systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy
Patients with sickle cell disease (SCD) and thalassemia experience several complications across their lifespan that lead to impairment in different health-related quality of life (HRQOL) domains. There is increasing interest in curative therapies for patients with SCD and thalassemia, including hematopoietic stem cell transplant (HSCT) and gene therapy; however, the effect of these therapies on various HRQOL domains remains unclear. Our objective was to systematically evaluate the most recent evidence for the effect of HSCT and gene therapy on HRQOL in patients with SCD and thalassemia. A systematic search of medical literature databases was conducted. A total of 16 studies (thalassemia, n = 9; SCD, n = 6; both, n = 1) involving 517 participants met inclusion criteria (thalassemia, n = 416; SCD, n = 101). HSCT was associated with a small to large positive effects in most HRQOL domains (Cohen’s d; mean = 0.47; median = 0.37; range, 0.27-2.05). In thalassemia, HSCT was frequently associated with large positive effects in physical and emotional HRQOL domains (median d = 0.79 and d = 0.57, respectively). In SCD, HSCT was associated with large positive effects in all HRQOL domains. Emerging data suggest improvement in HRQOL outcomes across different domains following gene therapy in thalassemia and SCD. The quality of evidence was moderate in 13 studies (81%). HSCT has a positive impact on several HRQOL domains in patients with SCD and thalassemia; however, more longitudinal studies are warranted to assess the sustainability of these effects. Reporting HRQOL outcomes from ongoing gene therapy or gene-editing trials in SCD and thalassemia is key to better understand the benefits of such therapies.
- Open Access
- 1 March 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (3) , 556-561
Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients
- 1 March 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (3) , 556-561
Open AccessImmune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients
- Open Access
- 1 February 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (2) , 321-327
Practice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia
- 1 February 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (2) , 321-327
Open AccessPractice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia
- Open Access
- 1 October 2017
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 23 (10) , 1695-1700
A Multicenter Retrospective Analysis Stressing the Importance of Long-Term Follow-Up after Hematopoietic Cell Transplantation for β-Thalassemia
- 1 October 2017
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 23 (10) , 1695-1700
Open AccessA Multicenter Retrospective Analysis Stressing the Importance of Long-Term Follow-Up after Hematopoietic Cell Transplantation for β-Thalassemia
- Open Access
- 1 June 2016
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 22 (6) , 1056-1064
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis
- 1 June 2016
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 22 (6) , 1056-1064
Open AccessOutcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis
- 23 December 2015
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 57 (4) , 949-952
Long-term follow-up of children with chronic myeloid leukemia after hematopoietic stem cell transplantation and tyrosine kinase inhibitor therapy
Chronic myeloid leukemia (CML) is a rare malignancy in the pediatric population, accounting for less than 2% of pediatric leukemia.[1] Before the introduction of tyrosine kinase inhibitors (TKI), a...
- 23 December 2015
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 57 (4) , 949-952
Long-term follow-up of children with chronic myeloid leukemia after hematopoietic stem cell transplantation and tyrosine kinase inhibitor therapy
Chronic myeloid leukemia (CML) is a rare malignancy in the pediatric population, accounting for less than 2% of pediatric leukemia.[1] Before the introduction of tyrosine kinase inhibitors (TKI), a...